Short Interest in Jaguar Health Inc (NASDAQ:JAGX) Drops By 88.5%

Jaguar Health Inc (NASDAQ:JAGX) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 135,900 shares, a drop of 88.5% from the May 15th total of 1,184,100 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average trading volume of 311,100 shares, the days-to-cover ratio is presently 0.4 days.

Shares of JAGX traded down $0.12 during mid-day trading on Wednesday, hitting $4.84. The stock had a trading volume of 323,700 shares, compared to its average volume of 196,579. The company has a market capitalization of $6.95 million, a price-to-earnings ratio of -0.03 and a beta of 1.26. The stock’s fifty day moving average price is $2.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.18 and a current ratio of 0.30. Jaguar Health has a 52 week low of $3.89 and a 52 week high of $175.00.

Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($13.29) by $0.70. The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $2.20 million. Jaguar Health had a negative return on equity of 372.84% and a negative net margin of 667.59%. As a group, research analysts predict that Jaguar Health will post -34.63 earnings per share for the current year.

JAGX has been the topic of a number of recent analyst reports. ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Zacks Investment Research upgraded Jaguar Health from a “sell” rating to a “hold” rating in a report on Saturday. Finally, HC Wainwright reiterated a “buy” rating on shares of Jaguar Health in a report on Monday, April 15th.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

See Also: Why do companies issue stock splits?

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.